Centre Asset Management LLC Has $9.41 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

Centre Asset Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 6.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 371,257 shares of the biopharmaceutical company's stock after selling 26,233 shares during the period. Pfizer comprises 2.4% of Centre Asset Management LLC's portfolio, making the stock its 11th biggest position. Centre Asset Management LLC's holdings in Pfizer were worth $9,408,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. Rialto Wealth Management LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Clarity Asset Management Inc. acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC increased its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $28,000. Finally, Bernard Wealth Management Corp. acquired a new stake in Pfizer during the 4th quarter worth $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of research firms have commented on PFE. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a report on Monday, March 10th. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Cantor Fitzgerald began coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. UBS Group lifted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of "Moderate Buy" and a consensus target price of $29.17.

Pfizer Stock Up 0.0%

PFE traded up $0.01 during trading on Friday, hitting $23.46. The company had a trading volume of 56,576,195 shares, compared to its average volume of 41,238,850. The company has a market capitalization of $133.38 billion, a PE ratio of 16.64, a PEG ratio of 0.64 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The firm's 50-day moving average price is $23.12 and its 200 day moving average price is $25.07. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.82 EPS. As a group, equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be given a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.33%. Pfizer's dividend payout ratio is currently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.